When Ports for Keytruda or Chemo...& etc,,,
Lawsuits are ongoing against manufacturers of certain chemo port catheters, most notably Bard PowerPorts, alleging design defects, such as the use of ChronoFlex, that lead to catheter fracture, migration, infection, and blood clots.
As of April 2026, over 3,200 federal lawsuits have been consolidated into a Multidistrict Litigation (MDL 3081).
ClassAction.org
Key Aspects of the Chemo Port Lawsuits
Targeted Devices:
The majority of lawsuits focus on the Bard PowerPort, particularly those with a mixture of polyurethane and barium sulfate (ChronoFlex), which plaintiffs claim degrades and causes fractures.
Primary Injuries:
Alleged injuries include thrombosis (blood clots), pulmonary embolism, infection, sepsis, cardiac injuries, and perforation of organs or tissues.
Allegations:
Lawsuits allege that manufacturers knew of the risks, failed to properly test devices, and failed to adequately warn patients and doctors of these complications.
Legal Status:
A federal MDL (MDL 3081) was established in August 2023, consolidating cases. The first bellwether trial is scheduled for April 21, 2026, to test the evidence.
Who May Qualify:
Patients who received a Bard PowerPort or other implanted port that failed, causing serious injury requiring surgery, hospitalization, or causing death.
ClassAction.org
Commonly Named Manufacturers
While Bard Access Systems, Inc. and its parent company, Becton, Dickinson and Company (BD), are the main targets, lawsuits also involve AngioDynamics Inc..
Seeger Weiss LLP
___
Always post reminders of no Leronlimab side affects lawsuits. Never thought about Port delivery need & their lawsuits until the other day, after reading / posting, Keytruda as Sub-q, does sometimes require a Port.
The number of Leronlimab advantages is simply mind-blowing.
Lawsuits are ongoing against manufacturers of certain chemo port catheters, most notably Bard PowerPorts, alleging design defects, such as the use of ChronoFlex, that lead to catheter fracture, migration, infection, and blood clots.
As of April 2026, over 3,200 federal lawsuits have been consolidated into a Multidistrict Litigation (MDL 3081).
ClassAction.org
Key Aspects of the Chemo Port Lawsuits
Targeted Devices:
The majority of lawsuits focus on the Bard PowerPort, particularly those with a mixture of polyurethane and barium sulfate (ChronoFlex), which plaintiffs claim degrades and causes fractures.
Primary Injuries:
Alleged injuries include thrombosis (blood clots), pulmonary embolism, infection, sepsis, cardiac injuries, and perforation of organs or tissues.
Allegations:
Lawsuits allege that manufacturers knew of the risks, failed to properly test devices, and failed to adequately warn patients and doctors of these complications.
Legal Status:
A federal MDL (MDL 3081) was established in August 2023, consolidating cases. The first bellwether trial is scheduled for April 21, 2026, to test the evidence.
Who May Qualify:
Patients who received a Bard PowerPort or other implanted port that failed, causing serious injury requiring surgery, hospitalization, or causing death.
ClassAction.org
Commonly Named Manufacturers
While Bard Access Systems, Inc. and its parent company, Becton, Dickinson and Company (BD), are the main targets, lawsuits also involve AngioDynamics Inc..
Seeger Weiss LLP
___
Always post reminders of no Leronlimab side affects lawsuits. Never thought about Port delivery need & their lawsuits until the other day, after reading / posting, Keytruda as Sub-q, does sometimes require a Port.
The number of Leronlimab advantages is simply mind-blowing.
2
